Results 121 to 130 of about 5,286 (232)

Modular Rh‐Catalyzed Synthesis and Biological Profiling of Diverse Pentafluorobenzenesulfonamide Reactive Fragments

Chemistry – A European Journal, Volume 32, Issue 24, 23 June 2026.
A modular Rh‐catalyzed synthetic approach enabled the preparation of diverse reactive fragments from available substrates. The reactive fragments modified Aurora A kinase via several distinct modification reaction classes. In a complex biological environment, the constellation of modified proteins depended critically on the reactive fragment structure.
Julian Chesti, Jennifer A. Miles, George J. Wade, Scott Grossman, George W. Preston, Richard Bayliss, Stuart L. Warriner, Megan H. Wright, Adam Nelson   +8 more
wiley   +1 more source

Identification of nine novel mutations in the Bruton's tyrosine kinase gene in X-linked agammaglobulinaemia patients

, 2000
Mutations in the Bruton's tyrosine kinase (BTK ) gene are responsible for X-linked Agammaglobulinemia (XLA), an immunodeficiency caused by a block in B cell differentiation.
ROSSI, PAOLO, Orlandi, P, Angelini, F, Rossi, P, ANGELINI, FEDERICA, Moschese, V, Plebani, A, Ritis, K, Speletas, M, Arvanitidis, K, MOSCHESE, VIVIANA, Sideras, P   +11 more
core   +1 more source

Bruton’s Tyrosine Kinase Inhibitors: Recent Updates

International Journal of Molecular Sciences
Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the landscape for the treatment of hematological malignancies, solid tumors, and, recently, autoimmune disorders. The BTK receptor is expressed in several hematopoietic cells such as macrophages, neutrophils, mast cells, and osteoclasts.
Amneh Fares, Carlos Carracedo Uribe, Diana Martinez, Tauseef Rehman, Carlos Silva Rondon, Jose Sandoval-Sus   +5 more
openaire   +2 more sources

Stage‐Dependent Transcriptional Reprogramming of B‐Cell Receptor Signaling and Antigen Presentation During Bovine Leukemia Virus–Driven Lymphomagenesis

Animal Genetics, Volume 57, Issue 3, June 2026.
ABSTRACT Bovine leukemia virus (BLV), an oncogenic deltaretrovirus, establishes lifelong infection in cattle and induces enzootic bovine leukosis in a subset of animals following prolonged latency. Despite extensive evidence of immune dysregulation, stage‐specific transcriptional reprogramming of B cells, the primary viral reservoir remains ...
Mohammad Mehdi Akbarin, Zahra Farjami, Cecilia Rodríguez Murillo, Víctor David González‐Fernández, Gabriel Eduardo Acevedo‐Jiménez, Lucero de María Ávila‐De la Vega, Hugo Ramírez Álvarez   +6 more
wiley   +1 more source

Allosteric regulation and targeting of Bruton's tyrosine kinase (Btk) in B-cell lymphoma

, 2020
Bruton's tyrosine kinase (Btk) is a key component of BCR signaling required for B-cell maturation and activation. Loss-of-function mutations throughout the Btk protein cause human X-linked agammaglobulinemia (XLA), a heritable genetic disorder ...
Pereira Duarte, Daniel
core   +1 more source

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors

Frontiers in Immunology, 2021
C. I. Edvard Smith, Jennifer R. Brown, Rula Zain, Rula Zain   +3 more
doaj   +1 more source

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study

Cancer Medicine, Volume 15, Issue 6, June 2026.
In a real‐world matched cohort study of treatment‐naïve TP53 wild‐type CLL patients, venetoclax plus obinutuzumab demonstrated significantly longer time to next treatment and improved 4‐year overall survival compared to first‐line acalabrutinib. Despite higher rates of cytopenias and infections, the venetoclax‐based regimen showed superior efficacy ...
Po‐Wei Liao, Bor‐Sheng Ko, Yu‐Chen Su, Wei‐Ting Chao, Chieh‐Lin Jerry Teng   +4 more
wiley   +1 more source

Absence of Bruton's tyrosine kinase (Btk) mutations in patients with acute myeloid leukaemia

, 1998
Bruton's tyrosine kinase (Btk) is a non-receptor protein tyrosine kinase (PTK) that is expressed in all haemopoietic lineages except mature T cells and plasma cells. Despite the broad range of expression.
Kanariou, M, ROSSI, PAOLO, Orlandi, P, Tsironidou, V, Rossi, P, Pardali, E, Ritis, K, Speletas, M, Sideras, P, Skordala, M, Sideras, P., Moschese, V, Kartalis, G, Bourikas, G, MOSCHESE, VIVIANA   +14 more
core   +1 more source

IGLV3‐21R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract IGLV3‐21R110 is a point mutation enabling autonomous B‐cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL). It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients treated with Bruton tyrosine kinase inhibitors.
Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Palash C. Maity, Armin Riecke, Christof Schneider, Billy M. C. Jebaraj, Rashmi P. Dheenadayalan, Hassan Jumaa, Marc Young, Manish Kumar, Lothar Müller, Ursula Vehling‐Kaiser, Michael Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna‐Maria Fink, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Petra Langerbeins, Eugen Tausch, Stephan Stilgenbauer   +24 more
wiley   +1 more source

Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario

Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian ...
Carlo Visco, Pier Luigi Zinzani, Antonio Pinto, Maurizio Martelli, Emanuele Guardalben, Marco Ladetto, Francesco Zaja   +6 more
core